Late Tuesday, Abbvie And Genmab Announced Topline Results From The Follicular Lymphoma Cohort Of The Phase 1/2 EPCORE NHL-1 Trial Of Epcoritamab,; The Companies Will Engage Regulatory Authorities To Discuss Next Steps
Portfolio Pulse from Benzinga Newsdesk
Abbvie and Genmab have announced the topline results from the follicular lymphoma cohort of the phase 1/2 EPCORE NHL-1 trial of Epcoritamab. The companies are planning to engage with regulatory authorities to discuss the next steps.
June 28, 2023 | 8:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Abbvie's phase 1/2 EPCORE NHL-1 trial of Epcoritamab has reached a significant milestone with the announcement of topline results. The company will now engage with regulatory authorities for further steps.
The announcement of topline results is a significant milestone in the development of a drug. This could potentially lead to positive investor sentiment and an increase in Abbvie's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Genmab has announced the topline results from the phase 1/2 EPCORE NHL-1 trial of Epcoritamab. The company will now engage with regulatory authorities to discuss the next steps.
The announcement of topline results is a significant milestone in the development of a drug. This could potentially lead to positive investor sentiment and an increase in Genmab's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100